Esperion Therapeutics, Inc. (ESPR)
2.775
+0.02
(+0.54%)
USD |
NASDAQ |
Mar 26, 10:36
Esperion Therapeutics Cash from Financing (Quarterly) : 30.16M for Dec. 31, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Nektar Therapeutics | 38.67M |
| Harrow, Inc. | -5.044M |
| Catalyst Pharmaceuticals, Inc. | -25.58M |
| Rigel Pharmaceuticals, Inc. | -4.572M |
| CytomX Therapeutics, Inc. | 16.64M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 45.24M |
| Free Cash Flow | -13.09M |
| Free Cash Flow Per Share (Quarterly) | 0.159 |
| Free Cash Flow to Equity (Quarterly) | 98.23M |
| Free Cash Flow to Firm (Quarterly) | 67.22M |
| Free Cash Flow Yield | -2.15% |